logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Tianfeng Securities: Received government subsidies related to income amounting to 32.56 million yuan.

date
04/06/2025
Tianfeng Securities announced on the evening of June 2nd that its wholly-owned subsidiary received a government subsidy related to income of 32.56 million yuan on May 30th, accounting for 109.6% of the absolute value of the company's audited net profit attributable to its parent in 2024.
Latest
3 m ago
Hong Kong insurance stocks weakened in volatility, with Zhongan Online and China Property and Casualty Insurance dropping more than 2%, while Ping An Insurance and Yunfeng Financial fell more than 1%.
4 m ago
Some logistics stocks in Hong Kong fell, with Yuexinwan Holdings dropping nearly 5%, ZTO Express dropping over 3%, Kerry Logistics and Sinotrans Shipping falling more than 1%.
5 m ago
JPMorgan Chase: Bullish on short-term uptrend of US stocks, Broadcom (AVGO.US) earnings report and non-farm payrolls will be strong catalysts.
5 m ago
Hong Kong stock market anomaly | China Biopharmaceuticals (01177.HK) rose more than 6% and announced the Phase III clinical data of the combination of pembrolizumab and anlotinib at the ASCO 2025 annual meeting.
5 m ago
Guangda Securities: First to give Youjia Innovation (02431.HK) a "buy" rating, expected to benefit from the accelerated penetration of smart driving.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.